KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 1.00

Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.

Ruinuo Jia, Tanyou Shan, Anping Zheng, Yaowen Zhang, Ping Lu, Guifang Zhang, Feng Wang, Zhiqiao Xu, Guobao Zheng, Dongxia Tang, Weiguo Zhang, Wanying Li, Ruonan Li, Yibo Guo, Lina Liu, Xiaoyong Luo, Yingjuan Zheng, Zhiwei Chang, Qiming Wang, Xinshuai Wang, Xiaozhi Yuan, Guoqiang Kong, Shuoguo Li, Ruina Yang, Dan Zhou, Jing Ren, Weijiao Yin, Jingxia Li, Junqian Zhang, Ziqi Wang, Manxi Sheng, Bingyi Xu, Liuyan Li, Xiaoyi Liu, Zhihao Lu, Lixin Wan, Fuyou Zhou, Shegan Gao

J Clin Oncol 42(20) 2436-2445

PMID38710003
PMCIDPMC11227300
DOI10.1200/JCO.23.02009
发表日期2024-05-06
入排依据:命中用户提供的消化道肿瘤阳性参考集。
摘要

摘要

PURPOSE: This phase 3 trial aimed to compare the efficacy and safety of capecitabine or capecitabine plus oxaliplatin (XELOX) with those of fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: Patients were randomly assigned to receive two cycles of capecitabine, XELOX, or PF along with concurrent intensity-modulated radiation therapy. Patients in each arm were again randomly assigned to receive two cycles of consolidation chemotherapy or not. The primary end points were 2-year overall survival (OS) rate and incidence of grade ≥3 adverse events (AEs). RESULTS: A total of 246 patients were randomly assigned into the capecitabine (n = 80), XELOX (n = 85), and PF (n = 81) arms. In capecitabine, XELOX, and PF arms, the 2-year OS rate was 75%, 66.7%, and 70.9% (capecitabine v PF: hazard ratio [HR], 0.91 [95% CI, 0.61 to 1.35]; nominal P = .637; XELOX v PF: 0.86 [95% CI, 0.58 to 1.27]; P = .444); the median OS was 40.9 (95% CI, 34.4 to 49.9), 41.9 (95% CI, 28.6 to 52.1), and 35.4 (95% CI, 30.4 to 45.4) months. The incidence of grade ≥3 AEs during the entire treatment was 28.8%, 36.5%, and 45.7%, respectively. Comparing the consolidation chemotherapy with the nonconsolidation chemotherapy groups, the median OS was 41.9 (95% CI, 34.6 to 52.8) versus 36.9 (95% CI, 28.5 to 44) months (HR, 0.71 [95% CI, 0.52 to 0.99]; nominal P = .0403). CONCLUSION: Capecitabine or XELOX did not significantly improve the 2-year OS rate over PF in DCRT for inoperable locally advanced ESCC. Capecitabine showed a lower incidence of grade ≥3 AEs than PF did.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。